GlycoMimetics (GLYC) Competitors $0.25 -0.01 (-5.16%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.25 +0.00 (+0.73%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GLYC vs. PDSB, SKYE, JMAC, CTOR, ABOS, XCUR, APLT, MGX, CNTX, and VHAQShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include PDS Biotechnology (PDSB), Skye Bioscience (SKYE), Maxpro Capital Acquisition (JMAC), Citius Oncology (CTOR), Acumen Pharmaceuticals (ABOS), Exicure (XCUR), Applied Therapeutics (APLT), Metagenomi (MGX), Context Therapeutics (CNTX), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. PDS Biotechnology Skye Bioscience Maxpro Capital Acquisition Citius Oncology Acumen Pharmaceuticals Exicure Applied Therapeutics Metagenomi Context Therapeutics Viveon Health Acquisition PDS Biotechnology (NASDAQ:PDSB) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Does the MarketBeat Community believe in PDSB or GLYC? GlycoMimetics received 242 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 70.75% of users gave PDS Biotechnology an outperform vote while only 57.53% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes7570.75% Underperform Votes3129.25% GlycoMimeticsOutperform Votes31757.53% Underperform Votes23442.47% Is PDSB or GLYC more profitable? PDS Biotechnology's return on equity of -139.57% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% GlycoMimetics N/A -230.74%-177.39% Which has more risk and volatility, PDSB or GLYC? PDS Biotechnology has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Does the media prefer PDSB or GLYC? In the previous week, PDS Biotechnology had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 4 mentions for PDS Biotechnology and 3 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.75 beat PDS Biotechnology's score of 0.53 indicating that GlycoMimetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlycoMimetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of PDSB or GLYC? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by company insiders. Comparatively, 8.7% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer PDSB or GLYC? PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 469.62%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33GlycoMimetics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher valuation and earnings, PDSB or GLYC? GlycoMimetics has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$0.94-1.68GlycoMimetics$10K1,601.68-$37.88M-$0.46-0.54 SummaryPDS Biotechnology beats GlycoMimetics on 9 of the 17 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.02M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.548.9226.7719.71Price / Sales1,601.68253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book3.106.466.794.50Net Income-$37.88M$143.98M$3.23B$248.18M7 Day Performance-0.64%2.03%1.53%0.20%1 Month Performance8.38%4.11%10.06%12.37%1 Year Performance-12.08%-2.87%16.74%7.04% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics1.8807 of 5 stars$0.25-5.2%N/A-9.9%$16.02M$10,000.00-0.5450PDSBPDS Biotechnology1.5773 of 5 stars$1.46+2.8%$9.00+516.4%-55.6%$66.74MN/A-1.2620Gap UpSKYESkye Bioscience1.1286 of 5 stars$2.15+15.0%$16.60+672.1%-81.6%$66.60MN/A-2.6211Analyst ForecastGap UpJMACMaxpro Capital AcquisitionN/A$4.89+5.7%N/A+1,580.3%$65.66MN/A0.002,021Gap UpCTORCitius OncologyN/A$0.91+0.7%$3.00+229.7%N/A$65.11MN/A0.00N/AABOSAcumen Pharmaceuticals2.3982 of 5 stars$1.07flat$7.33+585.4%-72.7%$64.81MN/A-0.7820Analyst RevisionXCURExicure1.4615 of 5 stars$10.23+1.7%N/A+2,082.5%$64.63M$500,000.00-4.9450Gap UpAPLTApplied Therapeutics4.0295 of 5 stars$0.46-24.4%$6.10+1,238.0%-91.1%$64.54M$455,000.00-0.2830News CoverageAnalyst RevisionHigh Trading VolumeMGXMetagenomi1.3493 of 5 stars$1.71+3.0%$13.00+660.2%-76.8%$63.92M$45.26M-0.81236Gap UpCNTXContext Therapeutics2.8144 of 5 stars$0.71-0.8%$6.00+749.5%-66.0%$63.36MN/A-0.787VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading Volume Related Companies and Tools Related Companies PDS Biotechnology Alternatives Skye Bioscience Alternatives Maxpro Capital Acquisition Alternatives Citius Oncology Alternatives Acumen Pharmaceuticals Alternatives Exicure Alternatives Applied Therapeutics Alternatives Metagenomi Alternatives Context Therapeutics Alternatives Viveon Health Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLYC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
